In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
The tangled web of large outsourced providers
ICON’s $12 billion acquisition of PRA Health Sciences is discussed as part of the changing CRO landscape.
-
Good CROs make dream teams, great CROs make dynasties
Dr. Nuala Murphy, President of Clinical Research Services, provides expert commentary on the importance of partnerships between CROs and sponsors.
-
ICON acquisition confirms its status as a global powerhouse in clinical research
An interview in which CEO Dr. Steve Cutler provides an overview of ICON’s evolution and drivers over the past few years from the pandemic to the recent PRA Health acquisition.
-
The new cancer treatment frontier: Why clinical trials need to keep pace with innovations in cancer research
Andreas Dreps and Martin Lachs discuss the recent advances in cancer research and why oncology clinical trials must make use of these developments to stay ahead of the curve
-
Alzheimer’s: the search for a cure
An interview in which Peter Schueler discusses the current landscape of Alzheimer’s research and recently published study results.
-
Implications of COVID-19 on statistical design and analyses of clinical studies
Tim Victor, Head of Biostatistics at ICON, considers the challenges and risks to statistical integrity and how they can be mitigated.
-
ICON: What a difference a year makes as sales jump and PRA Health integration begins
In its first-quarter results, ICON saw revenue hit $858 million, up 17.9% on a constant currency basis on the year-ago period, with full-year 2021 revenue guidance boosted from a range of $3.2 billion to $3.3 billion to as much as $3.5 billion.
-
Smart people: Dr. Steve Cutler
PharmaTimes talks to Dr Steve Cutler, CEO at ICON plc, about the impact of the COVID pandemic and challenges of running large-scale vaccine trials.
-
How will NICE fare in a post-Brexit world?
In this article, ICON experts Caroline Delaitre-Bonnin, Emmanuel Lacharme and Manpreet Sidhu, consider how the UK drug pricing group, NICE, will be impacted post-Brexit.
-
Data Science: transforming the future of clinical trials
Gerard Quinn, VP of IT Innovation & Informatics, offers insights on the use of Machine Learning and Artificial Intelligence in clinical trials, and the potential benefits and challenges for CROs and sponsors (pages 16-17).
